

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 13D1105419	(X3) Date Survey Completed 12/04/2023
Name of Provider or Supplier Southern Idaho Pain Institute Pc	Street Address, City, State 120 Rose St N, Twin Falls, ID	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2000	<p>ENROLLMENT AND TESTING OF SAMPLES CFR(s): 493.801</p> <p>Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994.</p> <p>This CONDITION is not met as evidenced by: Based on a review of proficiency testing (PT) records from College of American Pathologists (CAP) and an interview with the general supervisor (GS) on 12/4/2023, the laboratory failed to enroll in proficiency testing for 2022. The findings include: 1. A review of proficiency testing records from CAP identified that the laboratory failed to enroll and participate in PT for all analytes performed by the laboratory in 2022. The analytes include: codeine, hydrocodone, norhydrocodone, morphine, oxycodone, noroxycodone, oxymorphone, noroxymorphone, fentanyl, norfentanyl, methadone, EDDP, Tramadol, O-DSMT, tapentadol, buprenorphine, norbuprenorphine, meperidine, normeperidine, nalbuphine, alorazilam, a-OH-Alprazolam, Clonazepam, 7-aminoclonazepam, diazepam, nordiazepam, Oxazepam, temazepam, lorazepam, carisoprodol, cyclobenzaprine, meprobamate, amphetamine, methamphetamine, phentermine, methylphenidate, 6-MAM, benzoylecgonine, MDA, MDMA, PCP, gabapentin, pregabalin, zaleplon, zolpidem, zolpidem phyenyl-4-COOH, zopiclone, amitriptyline, nortriptyline, Venlafaxine, duloxetine, fluoxetine, paroxetine, citalopram, sertraline, Ketamine, norketamine, nalaxone, propoxyphene, cotinine, Phenobarbital,</p>

THC-COOH, ethyl sulfate. 2. An interview with the GS on 12/4/2023 at 1:31 pm confirmed that the laboratory failed to enroll and participate in PT for all analytes for 2022. 3. The laboratory reports performing 202,800 tests annually.